SMALL CELL LUNG CANCER ( SCLC )

This early-phase study tests a new radioactive drug (225Ac-ABD147) in people with small cell lung cancer or large cell neuroendocrine lung cancer whose cancer has grown after platinum chemotherapy. The main goals are to check safety, find the best dose, and see if the drug can sh…

This study tests the drug pembrolizumab in about 1,600 people with various advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug can shrink or control the tumors. Participants receive pembrolizumab and are monitored for tumor respons…

This study tests tarlatamab, an experimental drug, in 252 adults with small cell lung cancer that has worsened after standard chemotherapy. The goal is to see if different dosing schedules can shrink tumors or stop them from growing. Participants receive tarlatamab intravenously …

This phase 3 study compares a new drug, tarlatamab, to standard treatments in 509 adults with small cell lung cancer that returned after initial chemotherapy. The main goal is to see if tarlatamab helps people live longer. Participants must have had only one prior platinum-based …

This study follows up to 400 people who previously received A2Bio gene therapy for various solid tumors, including lung, colon, and pancreatic cancers. The goal is to track long-term side effects and see how well the treatment effects last over time. No new treatment is given—par…

This study follows 160 people with lung cancer to see how their muscle mass, strength, and function relate to how well they tolerate treatment, their quality of life, and survival. Researchers want to understand why some patients struggle to complete their cancer therapy. The goa…